VanEck Rare Earth/Strategic Metals vs Zimmer Biomet Holdings Inc — how do they compare? VanEck Rare Earth/Strategic Metals trades at $71.1, while Zimmer Biomet Holdings Inc trades at $88.69 (market cap $17.20B). The key difference: Zimmer Biomet Holdings Inc pays a 1.08% dividend while VanEck Rare Earth/Strategic Metals pays none. Which is the better fit depends on your goals.
| REMX | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $107.71 |
52-Week Low | $49.22 | $79.58 |
Market Cap | — | $17.20B |
Enterprise Value | — | $24.25B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $69.85, down 3.88% amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average signals against zero bullish, though oscillators show some buying opportunity with RSI readings in oversold territory. Recent news highlights ongoing geopolitical tensions around rare earth supply chains, with China's export controls and US efforts to secure critical minerals driving volatility in the sector.
The ETF offers exposure to 38 global rare earth companies but carries high volatility (~50% annualized) and significant China concentration risk. While strategic metals demand remains strong for technology and defense applications, REMX is best suited as a satellite holding for aggressive portfolios due to its specialized nature and geopolitical sensitivities.
No Aura AI signal available yet.
Trailing returns across standard periods
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →